Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, announced that it has distributed to shareholders a mid-year update letter reviewing the company’s recent progress and clinical plans for the remainder of 2018 and 2019.
{iframe}http://investors.rexahn.com/news-releases/news-release-details/rexahn-issues-mid-year-shareholder-letter-review-recent-progress{/iframe}